Chronic kidney disease (CKD) represents an important health policy concern due to a growing population and its associated morbidity and mortality. Predicting the future burden of CKD overall and in high-risk populations such as patients with elevated albuminuria, type 2 diabetes (T2D) or heart failure is important if healthcare services are to be resourced properly. Epidemiological and health economic policy models provide a useful way by which to make such predictions, but methods vary. This study aims to compare and validate two different approaches to estimating the burden of CKD in the United Kingdom (UK), and to estimate how this is predicted to change by 2025. In partnership with AstraZeneca.